The model's full reasoning — Q2 2018 call → NOThe question asks whether management describes an identifiable piece of new business activity that has already started contributing partway through the reported period or is starting right now, and makes clear that the reported results captured only a partial, early slice of it, with the fuller run-rate arriving over the next few quarters as a matter of timing. Let me look for such a description in the transcript. Key candidates: 1. Calcimimetics - this is mentioned as evolving, moving from Part D to Part B, with a titration process. Rice says "we're probably two quarters in to two to four quarter process in order to get this sorted out." This suggests it's a transition that's partway through. But is this "new business activity"? It's more of a transition of an existing drug program. The reported results captured partial effect? Mike says "we will see some volatility in the development of Calcimimetics over the year" and "I indicated we expected the operating earnings effect of Calcimimetics on a net basis to be around $1 loss for the year. I'm continuing to indicate that as our expectation for 2018." This seems more like a transition with volatility, not necessarily a new contributor ramping up. 2. The Vifor/Fresenius Medical Care joint venture - Mike mentions "the cost associated with the Vifor developments is really the ramp related to the Veltassa developments in EMEA." This is about costs ramping, not revenue. And it's about investments, not a new contributor that's already contributing. 3. The Sound divestiture - that's a divestiture, not new business. 4. The next stage transaction - not closed yet, so not started. 5. China investment - "we're putting production capability in for PD" - this is investment, not yet contributing. 6. The ESCOs - "we're sitting in a place today where we're roughly at about 41,000 patients" - this is existing, not new. Let me look more carefully at the Calcimimetics discussion. Rice says: "Calcimimetics; they continue to evolve. As you remember, we're moving from Part D in David to Part B in Barry. Pharmacy to the clinics. We believe that we're probably two quarters in to two to four quarter process in order to get this sorted out with great clarity in detail." This is a transition of an existing drug from one reimbursement pathway to another. It's not really "new business activity" that's a new contributor.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.